Highlights:
• Noxopharm confirms second pipeline drug program
•Promising new approach to blocking glioblastoma multiforme growth and invasiveness
• Test compound passes crucial proof-of-principle test
• Estimated 230,000 deaths p.a. globally from cancers of the brain and spinal cord. Significant unmet need.
For more information, please download the attached PDF
Download this document
